QRSL1: A promising drug target for glutamyl-tRNA(Gln) amidotransferase subunit A, mitochondrial

Target Name: QRSL1

NCBI ID: G55278

QRSL1

QRSL1: A promising drug target for glutamyl-tRNA(Gln) amidotransferase subunit A, mitochondrial

Glutamyl-tRNA(Gln) amidotransferase subunit A (QRSL1) is a protein that plays a crucial role in the transfer of glutamyl-tRNA(Gln) from the cytoplasm to the mitochondria. It is a key enzyme in the mitochondrial protein synthesis pathway and is essential for the biosynthesis of many essential amino acids, including glutamyl-tRNA(Gln), which is vital for protein synthesis and cell growth. The dysfunction of QRSL1 has been implicated in various diseases, including cancer, neurodegenerative diseases, and metabolic disorders. As a result, targeting QRSL1 has become an attractive research topic in recent years.

QRSL1 function and localization

QRSL1 is a 21-kDa protein that is expressed in most tissues and cells. It is primarily localized to the mitochondria, where it is a key component of the mitochondrial protein synthesis pathway. QRSL1 is responsible for transferring glutamyl-tRNA(Gln) from the cytoplasm to the mitochondria, where it can be translated into proteins via the initiation complex I.

QRSL1 plays a critical role in the regulation of protein synthesis and cell growth. It is a negative regulator of the translation of long chains, which means that it prevents the translation of longer chains that are not needed for protein synthesis. Additionally, QRSL1 is involved in the regulation of protein folding and stability, as well as in the modulation of cellular signaling pathways.

Mutations in QRSL1 have been implicated in various diseases, including cancer, neurodegenerative diseases, and metabolic disorders. For example, studies have shown that QRSL1 mutations are associated with an increased risk of cancer (5) and that they can lead to the misfolding of proteins and the development of neurodegenerative diseases. In addition, QRSL1 mutations have been linked to metabolic disorders, such as obesity and type 2 diabetes.

Drug targeting QRSL1

The development of drug targeting strategies for QRSL1 is an attractive area of research, as it has the potential to treat various diseases that are associated with QRSL1 dysfunction. One of the most promising strategies is the use of small molecules that can inhibit QRSL1 function.

One approach to targeting QRSL1 is the use of inhibitors of the translation of longer chains. This strategy is based on the fact that QRSL1 is a negative regulator of translation, which means that it prevents the translation of longer chains that are not needed for protein synthesis. By inhibiting the translation of longer chains, QRSL1 can be effectively targeted and its dysfunction can be corrected.

Several small molecules have been shown to be effective inhibitors of QRSL1 function, including cyclic oligomers, such as cyclic glutamyl-tRNA(Gln) and cyclic glutamyl-glutamyl-tRNA(Gln). These molecules can bind to specific regions of QRSL1 and prevent it from functioning. Additionally, several structural studies have shown that these molecules have a unique binding site on QRSL1 that is distinct from its binding site on QRSL2.

Another approach to targeting QRSL1 is the use of antibodies that can specifically recognize and block its function. This strategy is based on the fact that QRSL1 is a protein that can be targeted by antibodies, which can be used to prevent its function in

Protein Name: Glutaminyl-tRNA Amidotransferase Subunit QRSL1

Functions: Allows the formation of correctly charged Gln-tRNA(Gln) through the transamidation of misacylated Glu-tRNA(Gln) in the mitochondria. The reaction takes place in the presence of glutamine and ATP through an activated gamma-phospho-Glu-tRNA(Gln)

The "QRSL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about QRSL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets